We'd like your feedback
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Contact the study team using the details below to take part. If there are no contact details below please ask your doctor in the first instance.
Extrapyramidal and movement disordersSymptoms and signs involving speech and voice
This information is provided directly by researchers, and we recognise that it isn't always easy to understand. We are working with researchers to improve the accessibility of this information. In some summaries, you may come across links to external websites. These websites will have more information to help you better understand the study.
Spasmodic dysphonia is a laryngeal disorder causing overstimulation of the laryngeal muscles leading to irregular speech patterns. Like most voice disorders,spasmodic dysphonia is associated with a lower quality of life and decreased employability. Botulinum toxin injections are the gold-standard treatment for Spasmodic Dysphonia. Botulinum toxin inhibits overstimulation of laryngeal muscles,causing patients' voices to have fewer irregular breaks.
Our tertiary centre provides botulinum toxin injections for Spasmodic Dysphonia patients. A service evaluation in 2021 was performed to understand the livelihood of Spasmodic Dysphonia patients and how the botulinum injection service could run more smoothly. The service evaluation revealed these patients' poor livelihood before receiving botulinum toxin. Hence,this study aims to interview 20 Spasmodic Dysphonia patients to better understand their social and economic problems,and whether botulinum toxin has impacted these problems. The interviews will be semi-structured interviews held in-person or online based on patient preference. We hope to present and publish this study to raise awareness.
Start dates may differ between countries and research sites. The research team are responsible for keeping the information up-to-date.
The recruitment start and end dates are as follows:
Observational type: Qualitative;
You can take part if:
You may not be able to take part if:
Below 18 years of age,and additional laryngeal conditions severely affecting voice.
Below are the locations for where you can take part in the trial. Please note that not all sites may be open.
The study is sponsored by MANCHESTER UNIVERSITY NHS FOUNDATION TRUST and funded by ENTUK .
Your feedback is important to us. It will help us improve the quality of the study information on this site. Please answer both questions.
Read full details
for Trial ID: CPMS 64019
You can print or share the study information with your GP/healthcare provider or contact the research team directly.
